Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
NUTM1
ALL
genes rearrangement
infant leukaemia
prenatal origin
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
received:
26
04
2024
accepted:
23
07
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
Rearrangement of NUTM1 gene (NUTM1r) is one of the most frequent aberrations occurring in infants (younger than 1 year at diagnosis) with B-cell precursor Acute Lymphoblastic Leukaemia (BCP-ALL). In this study we had the unique opportunity to analyze the umbilical cord blood (UCB) sample from one infant patient with NUTM1r BCP-ALL. Herein we reported for the first time that NUTM1r infant ALL arise prenatally, as both the patient-specific CUX1::NUTM1 fusion gene, as well as two IG/TR leukaemic markers were already present and detectable in the patient's UCB at birth. Our results clearly demonstrate the prenatal origin of NUTM1r infant BCP-ALL.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Comitato Maria Letizia Verga
Organisme : Fondazione Tettamanti
Organisme : Associazione Italiana per la Ricerca sul Cancro (AIRC)
ID : IG 2023 n.29175
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Charlab R, Racz R. The expanding universe of NUTM1 fusions in pediatric cancer. Clin Transl Sci. 2023;16(8):1331–1339.
Boer JM, Valsecchi MG, Hormann FM, Antic Z, Zaliova M, Schwab C, et al. Favorable outcome of NUTM1‐rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia. 2021;35(10):2978–2982.
Fazio G, Bardini M, De Lorenzo P, Grioni A, Quadri M, Pedace L, et al. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants. Blood. 2021;137(14):1980–1984.
Pincez T, Landry JR, Roussy M, Jouan L, Bilodeau M, Laramee L, et al. Cryptic recurrent ACIN1‐NUTM1 fusions in non‐KMT2A‐rearranged infant acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2020;59(2):125–130.
Hormann FM, Hoogkamer AQ, Beverloo HB, Boeree A, Dingjan I, Wattel MM, et al. NUTM1 is a recurrent fusion gene partner in B‐cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31‐12.2. Haematologica. 2019;104(10):e455–e459.
Zafar MN. FAB classification of acute leukaemia. J Pak Med Assoc. 1992;42(2):28–29.
Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–87.
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Classification of acute leukemias: reply from EGIL to Dr van Dongen. Leukemia. 1996;10(8):1363–1364.
Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood. 1996;87(3):1134–1139.
Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor‐prognosis patients with abnormalities of chromosome band 11q23. Blood. 1996;87(3):1123–1133.
Hilden JM, Smith FO, Frestedt JL, McGlennen R, Howells WB, Sorensen PH, et al. MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood. 1997;89(10):3801–3805.
Zangrando A, Intini F, te Kronnie G, Basso G. Validation of NG2 antigen in identifying BP‐ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study. Leukemia. 2008;22(4):858–861.
Prieto C, Lopez‐Millan B, Roca‐Ho H, Stam RW, Romero‐Moya D, Rodriguez‐Baena FJ, et al. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL‐rearranged infant B‐ALL. Leukemia. 2018;32(3):633–644.
Lopez‐Millan B, Sanchez‐Martinez D, Roca‐Ho H, Gutierrez‐Aguera F, Molina O, Diaz de la Guardia R, et al. NG2 antigen is a therapeutic target for MLL‐rearranged B‐cell acute lymphoblastic leukemia. Leukemia. 2019;33(7):1557–1569.
Lopez‐Millan B, Rubio‐Gayarre A, Vinyoles M, Trincado JL, Fraga MF, Fernandez‐Fuentes N, et al. NG2 is a target gene of MLL‐AF4 and underlies glucocorticoid resistance in MLL‐r B‐ALL by regulating NR3C1 expression. Blood. 2024; in press.
Grioni A, Fazio G, Rigamonti S, Bystry V, Daniele G, Dostalova Z, et al. A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B‐cell acute lymphoblastic leukemia. Hema. 2019;3(3):e250.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer‐Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real‐time quantitative PCR data. Leukemia. 2007;21(4):604–611.
Jansen MW, Corral L, van der Velden VH, Panzer‐Grumayer R, Schrappe M, Schrauder A, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia. 2007;21(4):633–641.
Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant‐06 protocol: results from an international phase III randomized study. J Clin Oncol. 2019;37(25):2246–2256.
Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant‐99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–250.
Tomizawa D, Miyamura T, Imamura T, Watanabe T, Moriya Saito A, Ogawa A, et al. A risk‐stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL‐10 trial. Blood. 2020;136(16):1813–1823.
Popov A, Tsaur G, Permikin Z, Henze G, Verzhbitskaya T, Plekhanova O, et al. Genetic characteristics and treatment outcome in infants with KMT2A germline B‐cell precursor acute lymphoblastic leukemia: results of MLL‐baby protocol. Pediatr Blood Cancer. 2023;70(4):e30204.
McClure BJ, Pal M, Heatley SL, Rehn J, Schutz C, Breen J, et al. Two novel cases of NUTM1‐rearranged B‐cell acute lymphoblastic leukaemia presenting with high‐risk features. Br J Haematol. 2022;196(6):1407–1411.
Bardini M, Spinelli R, Bungaro S, Mangano E, Corral L, Cifola I, et al. DNA copy‐number abnormalities do not occur in infant ALL with t(4;11)/MLL‐AF4. Leukemia. 2010;24(1):169–176.
Bardini M, Galbiati M, Lettieri A, Bungaro S, Gorletta TA, Biondi A, et al. Implementation of array based whole‐genome high‐resolution technologies confirms the absence of secondary copy‐number alterations in MLL‐AF4‐positive infant ALL patients. Leukemia. 2011;25(1):175–178.
Dobbins SE, Sherborne AL, Ma YP, Bardini M, Biondi A, Cazzaniga G, et al. The silent mutational landscape of infant MLL‐AF4 pro‐B acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2013;52(10):954–960.
Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL‐rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–337.
Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A. 1997;94(25):13950–13954.
Greaves M. Pre‐natal origins of childhood leukemia. Rev Clin Exp Hematol. 2003;7(3):233–245.
Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102(7):2321–2333.
Khabirova E, Jardine L, Coorens THH, Webb S, Treger TD, Engelbert J, et al. Single‐cell transcriptomics reveals a distinct developmental state of KMT2A‐rearranged infant B‐cell acute lymphoblastic leukemia. Nat Med. 2022;28(4):743–751.
Mann G, Cazzaniga G, van der Velden VH, Flohr T, Csinady E, Paganin M, et al. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: the 'big sister' of the infant disease? Leukemia. 2007;21(4):642–646.
Bardini M, Woll PS, Corral L, Luc S, Wittmann L, Ma Z, et al. Clonal variegation and dynamic competition of leukemia‐initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia. 2015;29(1):38–50.